Onco Actu du 21 septembre 2017

	3.1 Prévention - Tabac
Marlboro Man Wants Us All to Quit Smoking. Is He Crazy? [Bloomberg] Indeed, one could ask why Philip Morris International Inc. wants to make a down payment on its own funeral by backing the Foundation for a Smoke-Free World? Does it have a death wish? The answer, of course, is no.
	3.1.1 Prévention - Tabac - e-cigs
Quit smoking campaign Stoptober backs e-cigs for first time [BBC News] The annual Stoptober campaign in England is embracing e-cigarettes for the first time - in a sign vaping is being seen as the key to getting people to quit.
Just one e-cigarette might raise adrenaline in the heart [Reuters] For the experiment, researchers asked 33 healthy nonsmokers to come to a lab on different days to try an e-cigarette with nicotine, a nicotine-free alternative, and a sham device that wasn’t a real e-cigarette.
	3.7 Prévention - Alcool
Pills prescribed for alcoholism might not work, study finds [The Guardian] None of the five drugs has a body of reliable evidence behind it, say the scientists, even though one of the drugs, nalmefene, has been approved for use in the NHS by Nice, the National Institute for Health and Care Excellence. Another, baclofen, has generated huge excitement, especially in France, but has been linked to deaths.
	4.2 Dép., diag. & prono. - Génome
New toolkit helps nurses use genomics in patient care [NIH] Developed with input from clinical educators and administrators, the Method for Introducing a New Competency Genomics (MINC) website provides resources for nursing leaders at all levels of genomics competency, ranging from basic knowledge about genomics to its practical impact on healthcare systems and policies.
	4.7 Dép., diag. & prono. - Col de l'utérus
Cervical cancer services are the next frontier for universal healthcare coverage in LMICs [BMJ] We need sustained political commitment and strategic investments in cervical cancer prevention.
	5. Traitements
Alnylam Breaks Through [In the Pipeline] The problems of drug delivery and stability are some of the big reasons it’s taken so long to get to this point (the same goes for all oligonucleotide ideas), and even now they represent serious limitations.
After 20 Years, A Drug That Silences Genes Succeeds [Forbes] In 2006, Mello and Fire were awarded the Nobel Prize in Medicine. But making a medicine was far away. The key problem was how to get RNAi, which breaks down if it’s just injected into the bloodstream, into cells.
	5.1 Traitements - Pré-clinique
Researchers hit the brakes on lethal brain cancers in mice [NIH] In addition to working towards a better understanding of why gliomas are so dependent on neuroligin-3 for growth, Dr. Monje’s team is now hoping to initiate a clinical trial using an ADAM10 inhibitor in human glioma patients.
Overcoming the Challenges of Metastatic Cancer: An Interview with Dr. Rosandra Kaplan [NCI] So there’s a surge of interest in studying cancer in context, meaning in relation to all the other cells, factors, and systems in the body. It makes our research work more complicated, but I think it will lead to more effective therapies in the end.
	5.10 Traitements - Essais
Health Policy Forum considers whether, and how, to share clinical trial data [Stanford Medicine] The issue of data sharing in clinical trials is timely: Beginning in July 2018, most medical journals will require papers based on clinical trials to include a data sharing statement that clarifies how and whether data will be shared, although data sharing is not yet mandated.
FDA’s Janet Woodcock: the clinical trials system is ‘broken’ [EndPoints] The comment came at the end of Woodcock’s talk in which she also noted that use of master protocols (protocols for trials that look at multiple therapies in a single disease or a single treatment in multiple diseases) and the development of new clinical trial networks “need to be the future.”
	5.12 Immunothérapies
The big question: Will cancer immune therapy work for me? [AP] “We’re not looking at how the immune system changes,” but for what starting point works best with the drugs, he said. “What we’re seeing is that the kinds of cells you have in a tumor predict who’s going to respond.”
	5.12.1 Immunothérapies - partenariats
Arcus' cancer portfolio attracts $35M option deal from Japan's Taiho [FierceBiotech] Taiho is paying $35 million over three years for access to Arcus' portfolio of cancer immunotherapy candidates, which the company said is poised to deliver four clinical projects before the end of 2018.
	5.12.2 Immunothérapies - CAR-T
FDA Approval of Tisagenlecleucel [JAMA Oncology] The science underlying chimeric antigen receptor T cells (CAR-T) heralds a new era of treatment, and the list price of $475 000 for the new drug (delivered as a one-time infusion) definitively shattered oncology drug pricing norms.
	5.12.6 Immunothérapies - AMM
Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod [Reuters] In May, Bavencio (avelumab) was approved by the U.S. Food and Drug Administration to treat bladder cancer and in March to treat Merkel cell carcinoma.
	5.5 ASCO
Featured Research From 2017 Palliative and Supportive Care in Oncology Symposium Explores Communication, Quality of Life Issues for People With Cancer [ASCO] Co-sponsors announced today the four abstracts that will be included in the Press Program.
	6. Lutte contre les cancers
Egg freezing may not delay chemo for breast cancer patients [Reuters] For the study, researchers examined data from medical records for breast cancer patients between the ages of 18 and 45 who were referred to the UCSF Center for Reproductive Health between 2011 and 2017 before starting chemotherapy.
	6.10 Politiques
UK science seeks ‘a new and special relationship with the EU’ [Science] Well if you look at the paper that we put out [on 6 September], that makes it very clear that we see enormous value from European collaboration. And that we will be keen to put in place a new and special relationship with the EU that will make that possible and something that we can even build on and develop in years to come.
	6.10.1 Politiques (USA)
In Congress, a doctor becomes a cancer patient — and preaches candor [STAT] The decision to disclose prostate cancer is perhaps an easier one than in cases where the outlook is more bleak: Prostate cancer is one of the most common types of cancer in men, and most who are diagnosed with it do not die from it.
	6.5 Médecines alternatives
Tibetan yoga practice may improve sleep quality for breast cancer patients receiving chemotherapy [MD Anderson] The research, published in the journal Cancer, found that women who practiced Tibetan yoga at least two times a week reported less daytime disturbances, better sleep quality and sleep efficiency over time, compared to those practicing less often and to women in an active control group receiving usual care.
A $200 million gift promotes alternative therapies at a California medical school — and critics recoil [STAT] “This is ultimately a very bad thing,” said Dr. Steven Novella, a neurologist at Yale University and longtime critic of alternative therapies. “It’s putting emphasis and the imprimatur of a university on things that have been discarded as medical fraud for 50 years.”
	6.7.2 Applis
Why the Apple Watch won't replace your doctor anytime soon [CNN] "Software has to go beyond just reliability to showing that the software encounter actually leads to appropriate care for the patient," he said.
	6.8 Communication
The Biotech Devil’s Dictionary: Your guide to the inanities of industry jargon [STAT] Biotech can be a breeding ground for jargon, coded language, and outright nonsense, as investors and scientists probe the depths of linguistic absurdity to explain why the thing they do is just that much more special than all the other things out there.